Rob Rodrigues

Rob Rodrigues is a seasoned litigator specializing in high-stakes business and intellectual property disputes in Brazil. Renowned for his strategic acumen, Rob delivers unmatched expertise to FORTUNE 500 companies and dynamic startups alike. He expertly navigates complex legal landscapes, ensuring robust patent portfolio management for top-tier life sciences and telecommunications firms. His deep market insight positions him as a first-choice advisor for both acquisition and enforcement actions.

Rob's excellence has been recognized by a number of leading publications. In 2024, Lexology listed him as a Legal Influencer in Dispute Resolution. Chambers describes Rob as a "superb litigator", "a very competent professional", and "outstanding in providing business-oriented advice." Who's Who Legal praises "his top-tier practice advising clients on life sciences-related patent litigation." The Legal 500 reports that clients describe Rob as someone "who standards out for his strong background in both the IP area, both in terms of litigation and in relation to more technical topics." Client testimonials in IAM Strategy 300 laud him for his "deep understanding of IP issues and keen strategic insight, which he leverages to add value and monetise portfolios."

Throughout his career, Rob has spearheaded multiple preliminary injunction proceedings and trials for global companies in Brazil. He also facilitates monumental IP asset transactions, with a keen eye on managing risks.

A Stanford Law School LL.M. alumnus, Rob served as a lead editor of the Stanford Technology Law Review. He has contributed extensively to global technology law journals and currently holds an editorial role at the Kluwer IP Blog.

Education

LL.M. in Law, Science and Technology, from Stanford Law School.
‍
Residential Scholarship at Hoover IP2 Summer Teaching Institute.

J.D. from Universidade Federal do Rio de Janeiro (UFRJ).

Publications

English

Green Patents: encouraging sustainable innovation in Brazil (Kluwer Patent Blog, 2024).

Boom in Brazil’s Medical Device Market Creates Patent Infringement Issue (IPWatchDog, 2024).
‍
Vaccines in Development (Genetic Engineering & Biotechnology News, 2024).
‍
VIP Community on Path to Patents in Brazil, Comma Matters, and DOCX-related Errors (Voice of IP, 2024).
‍
Animal Health and Patent Litigation (Kluwer Patent Blog, 2024).

Brazilian Lawmaker Introduces Bill to Allow AI as Inventor (IPWatchdog, 2024).
‍
Brazil – Important updates on the new rules regulating administrative appeals (Kluwer Patent Blog, 2024).
‍
Brazilian Congressman introduces bill to allow AI as inventor (Kluwer Patent Blog, 2024).
‍
Artificial Intelligence and Quantum Computers are coming - with legal challenges (Chambers, 2024).
‍
Patent filings and divisionals in Brazil: The challenge to obtain IP protection (Kluwer Patent Blog, 2024).
‍
BRPTO latest efforts on harmonization and Fighting the backlog (Chambers, 2024).
‍
Brazil – BRPTO violates due process and publishes rules impacting appeals and patent examination (Kluwer Patent Blog, 2024).
‍
Brazil to introduce skinny labels for generic drugs (IAM, 2023).
‍
ANVISA approves skinny labeling in Brazil (Kluwer Patent Blog, 2023).
‍
Brazilian Supreme Court issues new guidance on landmark patent term adjustment decision (IAM, 2023).
‍
Food Labeling Regulation (FDLI, 2023).
‍
Brazilian government issues IP National Strategy guidelines for 2023-2025 (Kluwer Patent Blog, 2023).
‍
Sequence Listings In Divisional Applications – A Comparison Between The EPO and Brazilian Patent Office (Kluwer Patent Blog, 2023).
‍
Brazilian government resurrects its Partnership for Productive Development (PDP) program. A new threat to pharma IP rights

Brazil: The Patent Office is Considering Changing Terms for Requesting Examination and Amending Patent Applications (Kluwer Patent Blog, 2023).

The relevance of court-appointed examiners on patent cases in Brazil (Kluwer Patent Blog, 2023).
‍
Brazil: how to successfully amend claims during patent examination (Kluwer Patent Blog, 2023).
‍
Brazil Becoming Relevant Forum for Telecom Patent Litigation (IPWatchDog, 2023).

Brazil implements changes to facilitate the recordal of IP agreements (Kluwer Patent Blog, 2023). 

BRPTO New Report on 5G Patent Applications in Brazil (Kluwer Patent Blog, 2023). 

Annotation of patents: a threat to second medical use patents in Brazil? (Kluwer Patent Blog, 2023). 

Bacteriophages and the Pressing Problem of AntibioticResistance (Genetic Engineering & Biotechnology News, 2023). 

Patent Term Adjustment in Brazil at the centre of major battle for IP owners (IAM, 2023). 

Brazil – Christian Louboutin victory protects red sole as“unregistered” design IP (Wolters Kluwer, 2023). 

Double patenting and the Brazilian patent practice (Kluwer Patent Blog, 2023). 

Product-by-process claims in Brazil: how to obtain effective claims? (Kluwer Patent Blog, 2023). 

Brazil: Christian Louboutin succeeds with unregistered rights (IP Stars, 2023). 

Brazil: leading case allows revival of a patent application (Kluwer Patent Blog, 2023). 

Skinny label in Brazil: drug authority seeking to implement new regulations (Kluwer Patent Blog, 2023). 

The Amazon in the Limelight: An Opportunity for Biotech inBrazil (Genetic Engineering & Biotechnology News, 2023). 

Comments on Joint USPTO-FDA Collaboration Initiatives (Intellectual Property Owners Association (IPO), 2023). 

Startup valuation e cuidado com ativos intelectuais (Valor Econômico, 2023). 

Patenting antibody-related inventions in Brazil (IP Stars, 2023). 

Brazilian patent term decision quashed and other 2022 Latin America developments (IAM, 2023). 

Brazilian Supreme Court gives hope companies facing shortened patent terms (IAM, 2022). 

Biomedical R&D in Brazil: who owns IP rights? (The Legal 500, 2022). 

Framework for Analysis of Venue Selection for Global Patent Litigation: Strategic Considerations (The Sedona Conference, 2022). 

German Federal Court opens door more document transparency patent cases (JUVE Patent, 2022). 

Biomedical Innovation in Brazil: an update (Bioengineering,2022). 

An overview of post-grant opposition procedure in Brazil (IPStars, 2022). 

How Brazil is becoming a more favourable jurisdiction for life sciences patentes (IAM, 2022). 

Biotechnology/pharma patent litigation in Brazil: an update on preliminary injunctions (Kluwer Patent Blog, 2022). 

Post-filing experimental evidence: how to obtain patents inBrazil? (Kluwer Patent Blog, 2022). 

Brazil's patent term decision: impact and practical tips (IPStars, 2021). 

Bolsonaro vetoes Brazil’s first-of-a-king compulsory tech transfer law (IAM, 2021). 

Brazil’s patent term decision: impact and practical tips (IPStars, 2021). 

Brazilian Supreme Court considers ruling on patent case for the first time in this century (Journal of Intellectual Property Law &Practice, 2021). 

Thousands of patents at risk of cancellation in Brazil (IAM,2021). 

Brazilian Supreme Court Sets an earlier date to decide the fate on the 10-Year Patent Term (BRICS and Beyond, 2021). 

COVID-19: The impact on IP law and practice in Brazil (IPStars, 2020). 

Brazil: New Regulation of Cannabis-Based Drugs Coming Soon (FDLI, 2019). 

Brazil: Pharmacovigilance Risk in Evolving BiosimilarRegulation (FDLI, 2015).

Portuguese

Computadores quânticos e IA: novos desafios judiciais (Valor Econômico, 2024).

Divulgação do programa nacional Mover traz expectativas para o aumento de depósitos de patentes voltadas à tecnologia verde (Migalhas, 2024).
‍
Elon Musk x OpenAI: o que o litígio pode significar para o futuro da IA? (JOTA, 2024).
‍‍
Congresso vai discutir se IA pode ser inventora de pedido de patente (JOTA, 2024).
‍
Governo relança PDPs, preocupação com propriedade intelectual na indústria farmacêutica (Decisor Brasil, 2023).
‍
Listagem de sequências em pedidos divididos – uma comparação entre o EPO e INPI (Decisor Brasil, 2023).

‍INPI lança consulta pública sobre alterações em pedidos de patenteJOTA, 2023

‍Como ter sucesso ao emendar reivindicações durante o exame de patentes no BrasilDecisor Brasil, 202

Languages

Portuguese
English
Spanish